AbbVie obtains FDA approval for new Skyrizi indication

The Food and Drug Administration has approved AbbVie's Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints.

[Read more: AbbVie gets FDA nod for Skyrizi]

"Patients often do not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness they may be experiencing, potentially leading to a delay in diagnosis and treatment of psoriatic arthritis," said Thomas Hudson, senior vice president, research and development, chief scientific officer, AbbVie. "We're proud to expand the use of Skyrizi to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms."

[Read more: FDA gives AbbVie approval for ​​​Qulipta]

Skyrizi is approved to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, as well as to treat active psoriatic arthritis in adults.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading the development and commercialization of Skyrizi globally.